Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.61 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18865248 | 0.87 | MAOB (0.54) | MAOBP4HTMMEN1KMT2APTGS1 | |
| SCHEMBL20943909 | 0.80 | MAOB (0.54) | MAOBP4HTMMEN1KMT2ALMNA | |
| SCHEMBL30745095 | 0.80 | MAOB (0.54) | MAOBP4HTMMEN1KMT2ALMNA | |
| SCHEMBL29785617 | 0.78 | MAOB (0.61) | MAOBP4HTMMEN1KMT2ALMNA | |
| SCHEMBL14181066 | 0.78 | MAOB (0.68) | MAOBMEN1KMT2ALMNAPTGS1 | |
| SCHEMBL1921588 | 0.78 | P4HTM (0.57) | MAOBP4HTMMEN1KMT2APDGFRB | |
| SCHEMBL14430227 | 0.77 | MAOB (0.58) | MAOBP4HTMMEN1KMT2ACYP2C19 | |
| SCHEMBL20607705 | 0.77 | P4HTM (0.56) | MAOBP4HTMMEN1KMT2AMCL1 | |
| SCHEMBL10707032 | 0.77 | P4HTM (0.56) | P4HTMMEN1KMT2AALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1921639 | 0.77 | P4HTM (0.56) | MAOBP4HTMMEN1KMT2APDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3888658-B1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230071483-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-03-09 | — | — | US | disclosed |
| US-20230071483-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-03-09 | — | — | US | disclosed |
| US-11440917-B2 | EIF4A-inhibiting compounds and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2022-09-13 | — | — | US | disclosed |
| CN-108601788-B | EIF 4A-inhibiting compounds and methods relating thereto | 效应治疗股份有限公司 | 2021-10-22 | — | — | CN | disclosed |
| EP-3888658-A1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | Effector Therapeutics Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3888658-A1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | Effector Therapeutics Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3380101-B1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-10577378-B2 | EIF4A-inhibiting compounds and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10577378-B2 | EIF4A-inhibiting compounds and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20180298017-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2018-10-18 | — | — | US | disclosed |
| EP-3380101-A1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | Effector Therapeutics Inc. (US) | 2018-10-03 | — | — | EP | disclosed |
| US-9957277-B2 | eIF4A-inhibiting compounds and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957277-B2 | eIF4A-inhibiting compounds and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| WO-2017091585-A1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017091585-A1 | EIF4-A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2017-06-01 | — | — | WO | disclosed |
| US-20170145026-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170145026-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | MAOB 3586/4885P4HTM 1048/4885MEN1 2908/4885 |
| US-20230071483-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | MAOB 3586/4885P4HTM 1048/4885MEN1 2908/4885 |
| US-11440917-B2 | EIF4A-inhibiting compounds and methods related thereto | EIF4A1, EIF4A2, EIF4A3 | MAOB 3586/4885P4HTM 1048/4885MEN1 2908/4885 |
| US-20180298017-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | MAOB 3586/4885P4HTM 1048/4885MEN1 2908/4885 |
| US-10577378-B2 | EIF4A-inhibiting compounds and methods related thereto | EIF4A1, EIF4A2, EIF4A3 | MAOB 3586/4885P4HTM 1048/4885MEN1 2908/4885 |
| US-20170145026-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | MAOB 3586/4885P4HTM 1048/4885MEN1 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.